131 related articles for article (PubMed ID: 15703840)
1. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor.
McLaughlin PJ; Jaglowski JR; Verderame MF; Stack BC; Leure-Dupree AE; Zagon IS
Int J Oncol; 2005 Mar; 26(3):809-16. PubMed ID: 15703840
[TBL] [Abstract][Full Text] [Related]
2. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck.
Jaglowski JR; Zagon IS; Stack BC; Verderame MF; Leure-duPree AE; Manning JD; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Jul; 56(1):97-104. PubMed ID: 15791460
[TBL] [Abstract][Full Text] [Related]
3. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration.
McLaughlin PJ; Stack BC; Braine KM; Ruda JD; Zagon IS
Int J Oncol; 2004 Jan; 24(1):227-32. PubMed ID: 14654962
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck.
McLaughlin PJ; Verderame MF; Hankins JL; Zagon IS
Int J Mol Med; 2007 Mar; 19(3):421-8. PubMed ID: 17273790
[TBL] [Abstract][Full Text] [Related]
5. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
Zagon IS; McLaughlin PJ
Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
[TBL] [Abstract][Full Text] [Related]
6. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin.
Jaglowski JR; Stack BC
Cancer Lett; 2006 Nov; 243(1):58-63. PubMed ID: 16412572
[TBL] [Abstract][Full Text] [Related]
7. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor.
McLaughlin PJ; Zagon IS
Int J Oncol; 2006 Jun; 28(6):1577-83. PubMed ID: 16685459
[TBL] [Abstract][Full Text] [Related]
8. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
[TBL] [Abstract][Full Text] [Related]
9. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers.
Zagon IS; McLaughlin PJ
Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
[TBL] [Abstract][Full Text] [Related]
11. Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck.
McLaughlin PJ; Stack BC; Levin RJ; Fedok F; Zagon IS
Cancer; 2003 Apr; 97(7):1701-10. PubMed ID: 12655527
[TBL] [Abstract][Full Text] [Related]
12. Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice.
McLaughlin PJ; Levin RJ; Zagon IS
Cancer Lett; 2003 Sep; 199(2):209-17. PubMed ID: 12969794
[TBL] [Abstract][Full Text] [Related]
13. Opioids and differentiation in human cancer cells.
Zagon IS; McLaughlin PJ
Neuropeptides; 2005 Oct; 39(5):495-505. PubMed ID: 16169076
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro.
Lee JW; Park JK; Lee SH; Kim SY; Cho YB; Kuh HJ
Anticancer Drugs; 2006 Apr; 17(4):377-84. PubMed ID: 16549994
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
16. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor.
McLaughlin PJ; Levin RJ; Zagon IS
Int J Oncol; 1999 May; 14(5):991-8. PubMed ID: 10200353
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck.
McLaughlin PJ; Stucki JK; Zagon IS
Head Neck; 2012 Apr; 34(4):513-9. PubMed ID: 21584896
[TBL] [Abstract][Full Text] [Related]
18. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.
Cohen EE; Lingen MW; Zhu B; Zhu H; Straza MW; Pierce C; Martin LE; Rosner MR
Cancer Res; 2006 Jun; 66(12):6296-303. PubMed ID: 16778206
[TBL] [Abstract][Full Text] [Related]
20. Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck.
Younes MN; Yigitbasi OG; Yazici YD; Jasser SA; Bucana CD; El-Naggar AK; Mills GB; Myers JN
Arch Otolaryngol Head Neck Surg; 2007 Jan; 133(1):15-23. PubMed ID: 17224516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
